Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Core Insights - Shanghai Henlius Biotech, Inc. has entered into a license agreement with Dr. Reddy's Laboratories for the commercialization of its investigational daratumumab biosimilar HLX15 in 43 countries and regions, including 42 European countries and the U.S. [1] - The agreement allows Henlius to receive up to $131.6 million, which includes a$33 million upfront payment and additional milestone payments, along with potential royalties on annual net sales of HLX15 [2] Company Overview - Henlius will be responsible for the development, manufacturing, and commercial supply of HLX15, aiming to enhance its product reach in the European and U.S. markets [2] - Dr. Reddy's Laboratories operates in over 75 countries globally, providing a strong partnership for Henlius to expand its market presence [2]